{"cluster": 43, "subcluster": 6, "abstract_summ": "Moreover those biologics were originally investigated by Rheumatologists for the treatment of numerous rheumatic conditions, including macrophage activating syndrome (MAS), a similar form of storm that resembles the one occurring in COVID-19 patients (3).The COVID-19 pandemic has caused a sense of unease in the rheumatology community about the risk to patients with immune-mediated diseases, given their predisposition to infection due to underlying disease states and immunosuppressive therapies.In particular, subjects affected by connective tissue diseases (CTD) are known to have an increased infectious risk compared to the healthy population due to a general impairment of the immune system intrinsic to the autoimmune disease itself, the iatrogenic effect linked to the use of immunosuppressive drugs, and the high number of comorbidities that often complicate the clinical picture.[2,3].\u2022 A correct patient risk stratification is of paramount importance for the proper management of economic and human resources.The coronavirus disease 2019 (COVID-19) pandemic, caused by a novel coronavirus (SARS-CoV-2), has raised concerns among physicians and their patients with rheumatic diseases (RDs) as the risk of infection was believed to be increased due to altered immune system activity that is typical of RDs and possibly worsened by glucocorticoids and immunosuppressive drugs.[1]The paper reviews aspects of COVID-19 that pertain to rheumatology, including symptoms and signs akin to those observed in rheumatic disorders, risk of infection or severe course of the disease in patients with a pre-existing rheumatic disease and those receiving antirheumatic or immunosuppressive medication as well as potential applications of antirheumatic or anticytokine therapeutic strategies that are already applied in rheumatology (including chloroquine, hydroxychloroquine, tocilizumab, baricitinib, and others) for patients with COVID-19.The implications of COVID-19 are wide-ranging for specialties, like Rheumatology, where immunomodulatory therapies are prescribed, and there has been much trepidation amongst many healthcare professionals regarding the best course of management during this time.It is encouraging that none of the 123 pediatric rheumatology patients (primarily juvenile idiopathic arthritis) on background biological disease modifying anti-rheumatic drug (bDMARD) therapies in Milan, Italy surveyed over a 7-week period from February 25 through April 14, 2020 (during which time Covid-19 was hyper-endemic there) had either confirmed or suspected Covid-19 (2).The outbreak of COVID-19 in December 2019 in China has very quickly become a global health emergency with almost two million of infected patients worldwide.[1]", "title_summ": "Preliminary considerations regarding the risk of COVID-19 and disease severity in chronic gastrointestinal conditionsHigh-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019Consensus Statement On Immune Modulation in Multiple Sclerosis and Related Disorders During the COVID-19 Pandemic: Expert Group on Behalf of the Indian Academy of NeurologyCOVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: \u201cwhat the bleep do we know?\u201dThoughts on COVID-19 and autoimmune diseasesHeadache medication and the COVID-19 pandemicHow to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinionChildren's (and autoimmune patients) morbidity (and mortality) from Covid\u201019 is similar to the general population: immunologic rationale.Should coronavirus disease 2019 concern rheumatologists?COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis.COVID-19 and your rheumatology patients.", "title_abstract_phrases": "In particular, subjects affected by connective tissue diseases (CTD) are known to have an increased infectious risk compared to the healthy population due to a general impairment of the immune system intrinsic to the autoimmune disease itself, the iatrogenic effect linked to the use of immunosuppressive drugs, and the high number of comorbidities that often complicate the clinical picture.[2,3].How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion\u2022 A correct patient risk stratification is of paramount importance for the proper management of economic and human resources.So far children (and autoimmune patients) , who should be extremely fragile, rarely entered into the third phase \"the cytokine release syndrome\u2010CRS \" of COVID\u201019, leading only some patients to the Intensive Care Units (ICUs).Preliminary considerations regarding the risk of COVID-19 and disease severity in chronic gastrointestinal conditionsThe novel RNA betacoronavirus SARS-CoV-2 is driving great efforts in clinical and basic research and several studies of the epidemiology, risk factors, clinical and virological features of this infection are already available.It is encouraging that none of the 123 pediatric rheumatology patients (primarily juvenile idiopathic arthritis) on background biological disease modifying anti-rheumatic drug (bDMARD) therapies in Milan, Italy surveyed over a 7-week period from February 25 through April 14, 2020 (during which time Covid-19 was hyper-endemic there) had either confirmed or suspected Covid-19 (2).Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis.Thoughts on COVID-19 and autoimmune diseasesOver the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected.We speculate that lupus patients might be more susceptible for a more severe COVID-19 disease course and emphasize the importance of maintaining remission in lupus patients."}